SCHEMBL7046273

SCHEMBL7046273

COc1nn(-c2ccc(NC(=O)OCc3ccc(Cl)cc3)cc2)c(=O)o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.60
MGLL Q99685 3/20 0.60
LPL P06858 1/20 0.54
LIPC P11150 1/20 0.54
LIPE Q05469 1/20 0.54
ABHD16A O95870 1/20 0.48
MAPT P10636 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
POLB P06746 2/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
GAA P10253 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP3A4 P08684 1/20 0.45
LMNA P02545 2/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7043932 0.85 LPL (0.56) FAAHMGLLLPLLIPCLIPE
SCHEMBL2233406 0.80 ABHD16A (0.72) FAAHMGLLLPLLIPCLIPE
SCHEMBL7045650 0.79 MGLL (0.61) FAAHMGLLMAPTPOLBMEN1
SCHEMBL7046159 0.77 LPL (0.58) FAAHMGLLLPLLIPCLIPE
SCHEMBL6604642 0.76 LPL (0.62) FAAHMGLLLPLLIPCLIPE
SCHEMBL29499689 0.75 MGLL (1.00) FAAHMGLLLPLLIPCLIPE
SCHEMBL7042914 0.75 MGLL (1.00) FAAHMGLLLPLLIPCLIPE
SCHEMBL7044232 0.75 MGLL (0.68) FAAHMGLLMAPTPOLBNPC1
SCHEMBL7043147 0.75 MGLL (0.81) FAAHMGLLLPLLIPCLIPE
SCHEMBL6603718 0.74 LPL (0.69) FAAHMGLLLPLLIPCLIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 FAAH 46/4885MGLL 1542/4885LPL 1845/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE FAAH 142/4885MGLL 10/4885LPL 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.